Immunizations in the United States: Success, structure, and stress - A complex collaboration involving government, industry, providers, academe, professional societies, and third-party payers

Health Affairs

Volumn 24, Issue 3, 2005, Pages 599-610

  Orenstein, Walter A ^a   Douglas, R Gordon ^b   Rodewald, Lance E ^c   Hinman, Alan R ^d  

^a EMORY UNIVERSITY   (United States)

^b Emory University ^*  (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

^d Public Health Informatics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; VACCINE;

AUTISM; BIOLOGICAL WARFARE; CHICKENPOX; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPENSATION; CONGENITAL RUBELLA SYNDROME; DIPHTHERIA; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNIZATION; INFLUENZA; INTESTINE INTUSSUSCEPTION; MEASLES; MEDICAL RESEARCH; MUMPS; PERTUSSIS; POLICY; POLIOMYELITIS; PROPHYLAXIS; REVIEW; RUBELLA; SIDE EFFECT; SMALLPOX; STREPTOCOCCUS INFECTION; TETANUS; UNITED STATES; VACCINATION REACTION;

ADULT; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; COOPERATIVE BEHAVIOR; HUMANS; IMMUNIZATION PROGRAMS; PREVENTIVE MEDICINE; SAFETY; UNITED STATES; VACCINES;

EID: 20044396004     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.599     Document Type: Review

References (44)

1. "Ten Great Public Health Achievements - United States, 1900-1999," Morbidity and Mortality Weekly Report 48. no. 12 (1999): 241-241.
2. "Impact of Vaccines Universally Recommended for Children - United States, 1990-1998," Morbidity and Mortality Weekly Report 48, no. 12 (1999): 243-248.
3. H.Q. Nguyen, A.O. Jumaan, and J. F. Seward, "Decline in Mortality due to Varicella after Implementation of Varicella Vaccination in the United States," New England Journal of Medicine 352, no. 5 (2005): 450-458.
4. C.G. Whitney et al., "Decline in Invasive Pneumococcal Disease after the Introduction of Protein Polysaccharide Conjugate Vaccine," New England Journal of Medicine 348, no. 18 (2003): 1737-1746.
5. B. Flannery et al., "Impact of Childhood Vaccination on Racial Disparities in Invasive Streptococcus pneumoniac Infections," Journal of the American Medical Association 291, no. 18 (2004): 2197-2203.
6. U.S. Centers for Disease Control and Prevention, "National Immunization Survey, List of Tables, 2003," www.cdc.gov/nip/coverage/NIS/ 03/toc-03.htm (28 February 2005).
7. "Vaccination Coverage among Children Entering School - United States, 2002-03 School Year," Morbidity and Mortality Weekly Report 52, no. 33 (2003): 791-793.
8. A.B. Coffield et al., "Priorities among Recommended Clinical Preventive Services," American Journal of Preventive Medicine 21, no. 1 (2001): 1-9.
9. F. Zhou et al., "Economic Evaluation of Routine Childhood Immunization with Dtap, Td, hub, IPV, MMR, and Hepb Vaccines in the United States, 2001" (Unpublished paper, CDC, 2005).
10. R.I. Glass et al.. "The Epidemiology of Rotavirus Diarrhea in the United States: Surveillance and Estimates of Disease Burden", Journal of Infectious Diseases 174, Supp. 1 (1996): S5-S11.
11. G.K. Folkers and A.S. Fauci, "The Role of U.S. Government Agencies in Vaccine Research and Development," Nature Medicine 4, no. 5 Supp. (1998): 491-494.
12. N.W. Baylor and K. Midthun, "Regulation and Testing of Vaccines," in Vaccines, 4th ed., ed. S.A. Plotkin and W.A. Orenstein (Philadelphia: Elsevier, 2004). 1539-1556.
13. G.D. Douglas. "The Vaccine Industry" in Vaccines, ed. Plotkin and Orenstein, 47-51.
14. G.B. Ebbert and E.D. Mascolo, "Vaccine Manufacturing," in Vaccines, ed. Plotkin and Orenstein, 53-67.
15. L.K. Pickering and W.A. Orenstein, "Development of Pediatric Vaccine Recommendations and Policies," Seminars in Pediatric Infectious Diseases 13, no. 3 (2002): 148-154.
16. "Notice to Readers: Recommended Adult Immunization Schedule - United States, 2003-2004," Morbidity and Mortality Weekly Report 52, no. 40 (2003): 965-969.
17. Unpublished data, CDC.
18. W.A. Orenstein, L.E. Rodewald, and A.R. Hinman, "Immunization in the United States," in Vaccines, ed. Plotkin and Orenstein. 1357-1386.
19. A.R. Hinman, W.A. Orenstein, and L. Rodewald, "Financing Immunizations in the United States," Clinical Infectious Diseases 38, no. 10 (2004): 1440-1446.
20. CDC, "Vaccines for Children: Vaccine Supply Policy Public," 15 April 2003, www.cdc.gov/nip/vfc/st_immz_proj/data/vacc_supply_public_2002.htm (28 February 2005).
21. Unpublished data, CDC.
22. CDC, "National Immunization Survey, List of Tables, 2003."
23. Unpublished data, CDC.
24. Centers for Medicare and Medicaid Services, "Medicare Announces New Preventive Benefits and Physician Payment Increases in Final Physician Payment Rule for 2005," Press Release, 3 November 2004, www.cms.hhs.gov/media/ press/release.asp?Counter=1248 (28 February 2005).
25. P.J. Smith et al., "Overview of the Sampling Design and Statistical Methods Used in the National Immunization Survey," American Journal of Preventive Medicine 20, no. 4 Supp. (2001): 17-24.
26. "Vaccination Coverage among Children Enrolled in Head Start Programs, Licensed Child Care Facilities, and Entering School - United States, 2000-01 School Year," Morbidity and Mortality Weekly Report 52, no. 9 (2003): 175-180.
27. D.L. Bartlett, "Immunization Registry Progress - United States, January-December 2002," Morbidity and Mortality Weekly Report 53, no. 20 (2004): 431-433.
28. J.F. Seward et al., "Varicella Disease after Introduction of Varicella Vaccine in the United States, 1995-2000," Journal of the American Medical Association 287, no. 5 (2002): 606-611;
29. and A. Schuchat et al., "Active Bacterial Core Surveillance of the Emerging Infections Program Network," Emerging infectious Diseases 7, no. 1 (2001): 92-99.
30. F. Varricchio et al., "Understanding Vaccine Safety Information from the Vaccine Adverse Event Reporting System," Pediatric Infectious Disease Journal 23, no. 4 (2004): 287-294.
31. R.T. Chen et al., "Vaccine Safety Datalink Project: A New Tool for Improving Vaccine Safety Monitoring in the United States, the Vaccine Safety Datalink Team," Pediatrics 99, no. 6 (1997): 765-773.
32. T.V. Murphy et al., "Intussusception among Infants Given an Oral Rotavirus Vaccine," New England Journal of Medicine 344, no. 8 (2001): 564-572.
33. R.T. Chen, R.L. Davis, and K.M. Sheedy, "Safety of Immunizations," in Vaccines, ed. Plotkin and Orenstein, 1557-1581.
34. G. Evans, D. Harris, and E.M. Levine, "Legal Issues," in Vaccines, ed. Plotkin and Orenstein, 1591-1617.
35. G. Evans, D. Harris, and E.M. Levine, "Legal Issues," in Vaccines Ibid., 1591-1617.
36. HRSA, "National Vaccine Injury Compensation Program, Post-1988 Monthly Statistics Report," 28 January 2005, www.hrsa.gov/osp/vicp/ monthly_stats_post.htm (28 February 2005).
37. J.M. Santoli et al., "Strengthening the Supply of Routinely Recommended Vaccines in the United States: Recommendations from the National Vaccine Advisory Committee," Journal of the American Medical Association 290, no. 23 (2003): 3122-3128.
38. "Interim Influenza Vaccination Recommendations, 2004-05 Influenza Season," Morbidity and Mortality Weekly Report 53, no. 39 (2004): 923-924.
39. CDC, "CDC Vaccine Price List," 7 February 2005, www.cdc.gov/nip/vfc/cdc_vac_pricejist.htm (28 February 2005).
40. E.J. Gangarosa et al., "Impact of Anti-Vaccine Movements on Pertussis Control: The Untold Story," Lancet 351, no. 9099 (1998): 356-361.
41. "The Politics of Autism; Lawsuits and Emotion vs. Science and Childhood Vaccines" (Editorial), Wall Street Journal 29 December 2003.
42. "Public Health and Aging: Influenza Vaccination Coverage among Adults Aged >50 Years and Pneumococcal Vaccination Coverage among Adults Aged ≥65 Years - United States, 2002," Morbidity and Mortality Weekly Report 52, no. 41 (2003): 987-992.
43. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs" Journal of Health Economics 22, no. 2 (2003): 151-185.
44. G. Peter et al., "Lessons Learned from a Review of the Development of Selected Vaccines: National Vaccine Advisory Committee," Pediatrics 104, no. 4, Part 1 (1999): 942-950.